4/A//SEC Filing
Helsel Dave 4/A
Accession 0001140361-23-044839
CIK 0001275187other
Filed
Sep 20, 8:00 PM ET
Accepted
Sep 21, 9:23 PM ET
Size
9.3 KB
Accession
0001140361-23-044839
Insider Transaction Report
Form 4/AAmended
Helsel Dave
SVP Global Operations and R&D
Transactions
- Exercise/Conversion
Common Stock
2023-07-19+9,650→ 37,939 total - Tax Payment
Common Stock
2023-07-19$8.92/sh−3,477$31,015→ 34,462 total - Exercise/Conversion
Performance Right
2023-07-19−15,081→ 0 total→ Common Stock (15,081 underlying)
Footnotes (3)
- [F1]This acquisition of 9,650 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.
- [F2]The exempt disposition of 3,477 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.
- [F3]On July 14, 2020, the reporting person received a target grant of 15,081 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 9,650 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.
Documents
Issuer
ANGIODYNAMICS INC
CIK 0001275187
Entity typeother
Related Parties
1- filerCIK 0001543753
Filing Metadata
- Form type
- 4/A
- Filed
- Sep 20, 8:00 PM ET
- Accepted
- Sep 21, 9:23 PM ET
- Size
- 9.3 KB